As luminal subtype of breast cancer has activation of the PI3K/AKT pathway and the effect of monotherapy of PI3K/AKTis is moderate17, we sought to identify additional strategies that may increase the efficacy of AKTi by rational combination therapies that will increase synergy and overcome emergence of resistance. Here, PIK3CA is linked to breast carcinoma.